ClinicalTrials.gov
public full text
Public Domain
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage of the disease.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients#454070
- Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma#143669
- Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma#356540
- Restraint of melanoma progression by cells in the local skin environment.#327056
- Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma#871121
Record · ID 1045561
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive